ESBL Mediated Resistance In Pseudomonas Aeruginosa In CSOM Patients : An Emerging Threat To Clinical Therapeutics
ESBL Mediated Resistance in Pseudomonas aeruginosa in CSOM patients
Keywords:
Antimicrobial resistance, Cephalosporins, CSOM, ESBL, Pseudomonas aeruginosaAbstract
Background: Chronic Suppurative Otitis Media (CSOM) is a major cause of hearing retardation in developing countries, therefore diagnosis and management of CSOM is extremely important. Objectives: To determine the antimicrobial resistance & ESBL (extended spectrum beta lactamase) producing Pseudomonas aeruginosa. Methods: The study was conducted after ethical approval by ethical committee in the Department of Microbiology, Dr. S. N. Medical College Jodhpur, Rajasthan. Two pus swabs were collected with sterile cotton swabs from CSOM patients attending ENT OPD. Identification of Pseudomonas aeruginosa was done by standard phenotypic microbiological procedure. ESBL detection was done by Combined disk diffusion method & E test. Observations & Results: Out of 150 cases, 137 (91.34%) were culture positive and no growth were obtained from 13 (8.66%) cases. Peak age of presentation was 11-20 years. The Antibiogram for P. aeruginosa revealed that resistance was maximum against Ceftazidime (75.5%) and minimum against Imipenem (6%). Among the 53 Pseudomonas aeruginosa isolate, 13 (24.5%) were ESBL producers while 40 (57.5%) were non ESBL producers. Conclusion: Our study underlines the unique problem of ESBL mediated resistance, which has created a therapeutic challenge for the Clinicians and Microbiologists. [Ramesh A NJIRM 2017; 8(1):8-12]
References
2. Nalini K, Sumathi P. Detection of ESBL and cephalosporin’s in urinary tract isolates. J Pharm Biomed Sci. 2012;21:1-5.
3. Ibukun A, Tochukwu N, Tolu O. Occurrence of ESBL and MBL in clinical isolates of Pseudomonas aeruginosa From Lagos, Nigeria. Journal of American Science 2007; 3(4) : 81-85.
4. Bradford PA. Extended spectrum ß-lactamases in the 21st century: The characterization, epidemiology and the detection of this important resistance threat. Clin. Microbiol. Rev 2001; 14: 933-951.
5. Aggarwal R, Chaudhari U, Bala K. Detection of extended – spectrum β lactamases in Pseudomonas aeruginosa. Indian J Pathol Microbiol 2008;51(2): 222-24.
6. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?.Clin Infect Dis 2002 Mar 01;34(5):634–640. 7. Colle JG, Miles RS, Wan B. Tests for the identification of bacteria. In: Colle JG, Fraser AG, Marimon BP, Simmons A, Editors. Mackei and McCartney Practical Medical Microbiology, 14th ed. Edinburg: Chuchill Livingstone; 1996; 131-150.
8. Clinical and Laboratory Standards Institute 2012. Performance Standards for Antimicrobial Susceptibility Testing. 22ndinformational supplement. Clinical and Laboratory Standards Institute Wayne PA 2012:32(3).
9. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial disk tests; Approved Standards , 9th ed. CLSI Document M2-A9 , Vol. 26 No.1 Wayne PA 2006.
10. Susmita Kumari Sahu, MoningiVenkata Narasimham, Indrani Mohanty, Sanghamitra Padhi, Pritilata Panda, Banojini Parida,Microbiological Profile Of Chronic Suppurative Otitis Media And Invitro Antibiotic Sensitivity Pattern In A Tertiary Care Hospital, Otolaryngology Online Journal, Vol 4,No 4(2014).
11. Prakash M1, Lakshmi K2*, Anuradha S1, Swathi Gn1Bacteriological Profile And Their Antibiotic Susceptibility Pattern Of Cases Of Chronic Suppurative Otitis Media, Asian J Pharm Clin Res, Vol 6, Suppl 3, 2013, 210 212.
12. Umadevi S, Joseph NM, Kumari K, Easow JM, Kumar S, Stephen, Srirangarajet al. Detection of extendedspectrum beta lactamases, AmpC beta lactamases and metallo beta lactamases in clinical isolates of Ceftazidime resistant Pseudomonas aeruginosa. Braz J Microbiol. 2011;42:1284-1288.
13. Peshattiwar PD, Peerapur BV. ESBL and MBL mediated resistance in Pseudomonas aeruginosa: an emerging threat to clinical therapeutics. J ClinDiagn Res. 2011;5:1552-1554.
14. Aggarwal R, Chaudhary U, Bala K. Detection of extended-spectrum beta-lactamase in Pseudomonas aeruginosa. Indian J Pathol Microbiol.2008.
15. Bharti and P.C.Sharma, Prevalence of Extended spectrum beta lactamase (ESBL) producing Pseudomonas aeruginosa strains recovered from human patients inHimachal Pradesh, Indian Journal of Basic and Applied Medical Research; December 2014: Vol.-4, Issue- 1, P. 430-440.
16. Mathur P, Kapil A, Das B, Dhawan B. Prevalence of extended spectrum β-lactamase producing gram negative bacteria in a tertiary care hospital. Indian J Med Res. 2002;115:153-157.
17. Bakshi R, Walia G, Shikha J. Prevalence of extended spectrum β-lactamases in multidrug resistant strains of gram negative Bacilli. J Acad Indus Res. 2013;1:558-560.
18. Goel V, Hogade SA, Karadesai SG. Prevalence of extended-spectrum beta-lactamases, Amp C betalactamase and metallo-beta-lactamase producing Pseudomonas aeruginosa and Acinetobacter baumanniiin an intensive are unit in a tertiary care hospital. J SciSoc.. 2013; 40:28-31.
19. Al-Agamy MH, Shibl AM, Tawfik AF, Elkhizzi NA, Livermore DM. Extended spectrum and metallo beta lactamases among ceftazidime resistant Pseudomonas aeruginosa in Riyadh, Saudi Arabia. J Chemother.2011;24:97-100.
20. Jacobson KL, Cohen SH, Inciardi JF, King JH, Lippert WE, Iglesias T. The relationship between
antecedent antibiotic use and resistance to extended spectrum cephalosporin’s in Group I β-lactamase producing organisms. Clin Infect Dis. 1995; 21:1107-1113.
